Search

Rucaparib

[A249240] The drug was later approved by the European Commission in May 2018.[L42185] It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185]. … [A18745] Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality.

Vayarin

A slow response time of 12 weeks is an impediment to successful management of ADHD as only 41.6% of subjects prescribed Vayarin remained compliant for the duration of the study. … Vayarin is a novel therapy for ADHD that appears to be effective in several studies [L1501, L1502, L1503].

Omacetaxine mepesuccinate

Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. … Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies

Penpulimab

The use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events. … Penpulimab is a humanized monoclonal IgG1 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1).

Diflorasone

Diflorasone is a topical corticosteroid used to treat itching and inflammation of the skin.

Catumaxomab

Catumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. … Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122].

Garadacimab

[L53303,L53283] It is the first inhibitor of factor XIIa to receive market approval.[L53303] … [A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age.

Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen

at the site from which the graft is taken. … [L35505] It was developed as an alternative to autografting - the process by which a patient's own skin is harvested and grafted onto the burn site - which has the disadvantage of creating a new wound

Olipudase alfa

[L42740] ASMD is a rare lysosomal storage disease caused by mutations in the SMPD1 gene, leading to a deficiency in acid sphingomyelinase and the abnormal accumulation of the primary ASM substrate, sphingomyelin … [A251590] It is the first and only enzyme replacement therapy in the world for the treatment of Acid Sphingomyelinase Deficiency (ASMD), also known as Niemann–Pick disease.

(+)-menthol